Cargando…

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

BACKGROUND: To fully assess the various dimensions affected by schizophrenia, clinical trials often include multiple scales measuring various symptom profiles, cognition, quality of life, subjective well-being, and functional impairment. In this exploratory study, we characterized the relationships...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lei, Phillips, Glenn, Johnston, Joseph, Kinon, Bruce J, Ascher-Svanum, Haya, Kollack-Walker, Sara, Succop, Paul, Naber, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315753/ https://www.ncbi.nlm.nih.gov/pubmed/22204569 http://dx.doi.org/10.1186/1471-244X-11-203

Ejemplares similares

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
por: Chen, Lei, et al.
Publicado: (2013)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
por: Haynes, Virginia S, et al.
Publicado: (2012)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
por: Faries, Douglas, et al.
Publicado: (2012)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
por: Peng, Xiaomei, et al.
Publicado: (2011)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
por: Liu-Seifert, Hong, et al.
Publicado: (2007)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen, Lei, et al.
Publicado: (2013)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation
por: Matza, Louis S, et al.
Publicado: (2012)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
por: Kelin, Katarina, et al.
Publicado: (2010)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis
por: Fu, Haoda, et al.
Publicado: (2015)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Erratum to: Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis
por: Ascher-Svanum, Haya, et al.
Publicado: (2015)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
por: Lipkovich, Ilya A, et al.
Publicado: (2009)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aeg3mt12kjkibjhk3o08f253kp